KDR and hepatocellular carcinoma: CARES‐310 trial was a randomized, open‐label, international phase III study conducted in 95 sites over 13 countries and regions all over the world to explore the efficacy and safety of anti‐PD‐1 antibody camrelizumab combined with VEGFR2‐targeted tyrosine‐kinase inhibitor rivoceranib versus sorafenib in the first‐line treatment of HCC.